BIO-RAD LABORATORIES, INC.
BIOBio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
Drugs in Pipeline
65
Phase 3 Programs
29
Upcoming Catalysts
9
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
9 upcoming, 0 past
SA53-OS (phase 1) Phase 2 Results Expected
Primary completion for SA53-OS (phase 1) trial (NCT06578624) in Solid Tumor
SourceQLS-111 Ophthalmic Solution (0.015%) Phase 2 Results Expected
Primary completion for QLS-111 Ophthalmic Solution (0.015%) trial (NCT07354477) in Non-proliferative Diabetic Retinopathy (NPDR)
SourceVRB-101 Phase 2 Results Expected
Primary completion for VRB-101 trial (NCT07281937) in Obesity
SourceRecombinant Human Proteoglycan 4 Phase 2 Results Expected
Primary completion for Recombinant Human Proteoglycan 4 trial (NCT07118241) in Sjögren's Syndrome
SourceJMT101 Phase 3 Results Expected
Primary completion for JMT101 trial (NCT06735391) in Locally Advanced or Metastatic Non-squamous NSCLC
SourceJIN-A02 Phase 2 Results Expected
Primary completion for JIN-A02 trial (NCT05394831) in EGFR Mutant Advanced Non-small Cell Lung Cancer
SourceJMT108 Phase 2 Results Expected
Primary completion for JMT108 trial (NCT07280832) in Unresectable Locally Advanced or Metastatic Melanoma
SourceDR-01 Phase 2 Results Expected
Primary completion for DR-01 trial (NCT05475925) in LGLL - Large Granular Lymphocytic Leukemia
SourceLB1410 Phase 2 Results Expected
Primary completion for LB1410 trial (NCT06468358) in Solid Tumor
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Recombinant Hepatitis B vaccine
Immunogenicity
Vaccine
Healthy
BAT1806
Rheumatoid Arthritis
COVID-19 Protein Subunit Recombinant Vaccine
COVID-19
Epoetin Alfa
Anemia in End Stage Renal Disease
Pentavalen
Healthy
MCS-2 15 mg/day
Lower Urinary Tract Symptoms
Buntanetap/Posiphen
Alzheimer Disease
N1539
Pain, Post-operative
BAT2206
Plaque Psoriasis
Vi-DT Typhoid Conjugate Vaccine
Vaccine
VBI-S
Septic Shock
Haporine-S
Dry Eye Syndromes
DTP/HB/Hib Vaccine
Healthy
BAT2306
Plaque Psoriasis
Avacincaptad Pegol
Geographic Atrophy
TBI-1301
Synovial Sarcoma
Cyclophosphamide
Synovial Sarcomas
JMT101
Locally Advanced or Metastatic Non-squamous NSCLC
Jointstem
Knee Osteoarthritis
hMG subcutaneous injection
Infertility (IVF Patients)
Roxadustat
Anemia Associated With End Stage Renal Disease (ESRD)
Vicinium
Bladder Cancer
CKDB-501A
Glabellar Lines
MCS-2
Lower Urinary Tract Symptoms
FG-4592
Anemia
BAT5906 injection
Neovascular (Wet) Age-related Macular Degeneration
Recombinant Humanized Bispecific antibody against HER2，KN026
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Iclaprim
Skin Structures and Soft Tissue Infections
DR-01
LGLL - Large Granular Lymphocytic Leukemia
DEX-IN
Pain
conventional therapy plus low dose hUC-MSCs treatment
Liver Cirrhosis
JMT108
Unresectable Locally Advanced or Metastatic Melanoma
Intranasal Dexmedetomidine
Pain, Post-operative
CABA-201
Systemic Lupus Erythematosus
BXP154
Wound Bleeding
TBI-1401(HF10)
Melanoma Stage III
SA53-OS (phase 1)
Solid Tumor
PolyPEPI1018 CRC Vaccine
Colorectal Cancer
Monoclonal antibody BAT6026
Dermatitis, Atopic
CAM-101 10%
Dry Eye
LB1410
Solid Tumor
'SMT-NK' Inj (allogeneic Natural Killer cell)
Biliary Tract Cancer
H002 capsule
Non-small Cell Lung Cancer
LEU011
Tumor, Solid
Allogeneic umbilical cord mesenchymal stem cells
ST Elevation Myocardial Infarction
GB002 (seralutinib)
Pulmonary Arterial Hypertension
VRB-101
Obesity
BG1805
Leukemia, Myeloid, Acute
QLS-111 Ophthalmic Solution (0.015%)
Non-proliferative Diabetic Retinopathy (NPDR)
Brequinar
COVID-19 Infection
Bone marrow mesenchymal stem cells
Osteoarthritis, Knee
Endostar(Recombinant Human Endostatin Injection)
Advanced Non-small Cell Lung Cancer
VBC103
Participants With Advanced Solid Tumor Malignancies
AB103
Necrotizing Soft Tissue Infections
JIN-A02
EGFR Mutant Advanced Non-small Cell Lung Cancer
NH002 (Perflutren Lipid Microspheres) Injectable Suspension
Cardiac Disease
Recombinant Human Proteoglycan 4
Sjögren's Syndrome
tOPV pilot batch
Healthy
CD7 CAR-T
T-Cell Acute Lymphocytic Leukemia
SB1518
Hodgkin Lymphoma
SARS-CoV-2 Subunit Recombinant Protein Vaccine
COVID-19
QLS-111, 0.015%
Open-angle Glaucoma (OAG)
DTP/HB and Hib vaccine
Healthy
HLA-G-CAR.BiTE allogeneic γδ T cells
Solid Tumor
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Recombinant Hepatitis B vaccine | Phase 3 | Immunogenicity | - |
Vaccine | Phase 3 | Healthy | - |
BAT1806 | Phase 3 | Rheumatoid Arthritis | - |
COVID-19 Protein Subunit Recombinant Vaccine | Phase 3 | COVID-19 | - |
Epoetin Alfa | Phase 3 | Anemia in End Stage Renal Disease | - |
Pentavalen | Phase 3 | Healthy | - |
MCS-2 15 mg/day | Phase 3 | Lower Urinary Tract Symptoms | - |
Buntanetap/Posiphen | Phase 3 | Alzheimer Disease | - |
N1539 | Phase 3 | Pain, Post-operative | - |
BAT2206 | Phase 3 | Plaque Psoriasis | - |
Vi-DT Typhoid Conjugate Vaccine | Phase 3 | Vaccine | - |
VBI-S | Phase 3 | Septic Shock | - |
Haporine-S | Phase 3 | Dry Eye Syndromes | - |
DTP/HB/Hib Vaccine | Phase 3 | Healthy | - |
BAT2306 | Phase 3 | Plaque Psoriasis | - |
Avacincaptad Pegol | Phase 3 | Geographic Atrophy | - |
TBI-1301 | Phase 3 | Synovial Sarcoma | - |
Cyclophosphamide | Phase 3 | Synovial Sarcomas | - |
JMT101 | Phase 3 | Locally Advanced or Metastatic Non-squamous NSCLC | - |
Jointstem | Phase 3 | Knee Osteoarthritis | - |
hMG subcutaneous injection | Phase 3 | Infertility (IVF Patients) | - |
Roxadustat | Phase 3 | Anemia Associated With End Stage Renal Disease (ESRD) | - |
Vicinium | Phase 3 | Bladder Cancer | - |
CKDB-501A | Phase 3 | Glabellar Lines | - |
MCS-2 | Phase 3 | Lower Urinary Tract Symptoms | - |
FG-4592 | Phase 3 | Anemia | - |
BAT5906 injection | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration | - |
Recombinant Humanized Bispecific antibody against HER2，KN026 | Phase 3 | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | - |
Iclaprim | Phase 3 | Skin Structures and Soft Tissue Infections | - |
DR-01 | Phase 2 | LGLL - Large Granular Lymphocytic Leukemia | - |
DEX-IN | Phase 2 | Pain | - |
conventional therapy plus low dose hUC-MSCs treatment | Phase 2 | Liver Cirrhosis | - |
JMT108 | Phase 2 | Unresectable Locally Advanced or Metastatic Melanoma | - |
Intranasal Dexmedetomidine | Phase 2 | Pain, Post-operative | - |
CABA-201 | Phase 2 | Systemic Lupus Erythematosus | - |
BXP154 | Phase 2 | Wound Bleeding | - |
TBI-1401(HF10) | Phase 2 | Melanoma Stage III | - |
SA53-OS (phase 1) | Phase 2 | Solid Tumor | - |
PolyPEPI1018 CRC Vaccine | Phase 2 | Colorectal Cancer | - |
Monoclonal antibody BAT6026 | Phase 2 | Dermatitis, Atopic | - |
CAM-101 10% | Phase 2 | Dry Eye | - |
LB1410 | Phase 2 | Solid Tumor | - |
'SMT-NK' Inj (allogeneic Natural Killer cell) | Phase 2 | Biliary Tract Cancer | - |
H002 capsule | Phase 2 | Non-small Cell Lung Cancer | - |
LEU011 | Phase 2 | Tumor, Solid | - |
Allogeneic umbilical cord mesenchymal stem cells | Phase 2 | ST Elevation Myocardial Infarction | - |
GB002 (seralutinib) | Phase 2 | Pulmonary Arterial Hypertension | - |
VRB-101 | Phase 2 | Obesity | - |
BG1805 | Phase 2 | Leukemia, Myeloid, Acute | - |
QLS-111 Ophthalmic Solution (0.015%) | Phase 2 | Non-proliferative Diabetic Retinopathy (NPDR) | - |
Brequinar | Phase 2 | COVID-19 Infection | - |
Bone marrow mesenchymal stem cells | Phase 2 | Osteoarthritis, Knee | - |
Endostar(Recombinant Human Endostatin Injection) | Phase 2 | Advanced Non-small Cell Lung Cancer | - |
VBC103 | Phase 2 | Participants With Advanced Solid Tumor Malignancies | - |
AB103 | Phase 2 | Necrotizing Soft Tissue Infections | - |
JIN-A02 | Phase 2 | EGFR Mutant Advanced Non-small Cell Lung Cancer | - |
NH002 (Perflutren Lipid Microspheres) Injectable Suspension | Phase 2 | Cardiac Disease | - |
Recombinant Human Proteoglycan 4 | Phase 2 | Sjögren's Syndrome | - |
tOPV pilot batch | Phase 2 | Healthy | - |
CD7 CAR-T | Phase 2 | T-Cell Acute Lymphocytic Leukemia | - |
SB1518 | Phase 2 | Hodgkin Lymphoma | - |
SARS-CoV-2 Subunit Recombinant Protein Vaccine | Phase 2 | COVID-19 | - |
QLS-111, 0.015% | Phase 2 | Open-angle Glaucoma (OAG) | - |
DTP/HB and Hib vaccine | Phase 2 | Healthy | - |
HLA-G-CAR.BiTE allogeneic γδ T cells | Phase 2 | Solid Tumor | - |
Regulatory & News
Approvals, filings, and latest developments